Barclays
ADPT icon

Barclays’s Adaptive Biotechnologies ADPT Stock Holding History

Barclays’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.75M Buy
302,774
+224,215
+285% +$5.51M ﹤0.01% 1725
2026
Q2 		$1.69M Buy
78,559
+19,116
+32% +$293K ﹤0.01% 2443
2026
Q1 		$825K Sell
59,443
-219,679
-79% -$3.5M ﹤0.01% 2867
2025
Q4 		$4.53M Sell
279,122
-8,152
-3% -$133K ﹤0.01% 2295
2025
Q3 		$4.3M Sell
287,274
-75,360
-21% -$918K ﹤0.01% 2321
2025
Q2 		$4.22M Buy
362,634
+158,664
+78% +$1.44M ﹤0.01% 2267
2025
Q1 		$1.52M Sell
203,970
-62,096
-23% -$477K ﹤0.01% 2843
2024
Q4 		$1.6M Buy
266,066
+35,889
+16% +$198K ﹤0.01% 3071
2024
Q3 		$1.18M Buy
230,177
+137,936
+150% +$601K ﹤0.01% 3249
2024
Q2 		$334K Sell
92,241
-59,264
-39% -$188K ﹤0.01% 3283
2024
Q1 		$486K Sell
151,505
-76,350
-34% -$295K ﹤0.01% 3612
2023
Q4 		$1.12M Buy
227,855
+91,834
+68% +$419K ﹤0.01% 3360
2023
Q3 		$741K Buy
136,021
+11,112
+9% +$73.5K ﹤0.01% 2546
2023
Q2 		$838K Sell
124,909
-77,520
-38% -$576K ﹤0.01% 2416
2023
Q1 		$1.79M Sell
202,429
-396,135
-66% -$3.49M ﹤0.01% 2277
2022
Q4 		$4.57M Buy
598,564
+439,726
+277% +$3.42M ﹤0.01% 1694
2022
Q3 		$1.13M Buy
158,838
+85,119
+115% +$802K ﹤0.01% 2141
2022
Q2 		$596K Buy
73,719
+35,276
+92% +$310K ﹤0.01% 2745
2022
Q1 		$534K Sell
38,443
-297,365
-89% -$4.68M ﹤0.01% 2859
2021
Q4 		$9.42M Buy
335,808
+296,137
+746% +$9.08M ﹤0.01% 1298
2021
Q3 		$1.35M Buy
39,671
+16,499
+71% +$597K ﹤0.01% 2604
2021
Q2 		$947K Sell
23,172
-45,918
-66% -$1.79M ﹤0.01% 2693
2021
Q1 		$2.78M Sell
69,090
-32,850
-32% -$1.78M ﹤0.01% 2011
2020
Q4 		$6.03M Buy
101,940
+101,852
+115,741% +$5.25M ﹤0.01% 1411
2020
Q3 		$4K Sell
88
-23,381
-100% -$983K ﹤0.01% 5077
2020
Q2 		$1.14M Buy
23,469
+21,540
+1,117% +$785K ﹤0.01% 2643
2020
Q1 		$54K Buy
1,929
+1,623
+530% +$45.3K ﹤0.01% 5182
2019
Q4 		$9K Sell
306
-5,900
-95% -$169K ﹤0.01% 6107
2019
Q3 		$191K Sell
6,206
-8,125
-57% -$332K ﹤0.01% 5000
2019
Q2 		$693K Buy
+14,331
New +$635K ﹤0.01% 4045

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Barclays's ADPT Position: Q3 2026 in Review

Barclays increased its Adaptive Biotechnologies (ADPT) stake by 285% in Q3 2026, buying an estimated $5.51M and bringing the position to 302,774 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Barclays first reported a position in ADPT in Q2 2019 and has held it in 30 quarters since. The position peaked at $9.42M in Q4 2021. 154 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Barclays held 302,774 shares of Adaptive Biotechnologies worth $8.75M as of Q3 2026.
  • Barclays bought 224,215 Adaptive Biotechnologies shares in Q3 2026, an estimated $5.51M.
  • Adaptive Biotechnologies made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1725 holding.
  • Barclays first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 30 quarters since.
  • Barclays's Adaptive Biotechnologies position peaked at $9.42M in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.